• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
PublishDashboard
    Quantisnow Logo

    © 2025 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlertsPublish with Us
    Company
    AboutQuantisnow PlusContactJobsAI employees
    Legal
    Terms of usePrivacy policyCookie policy

    SEC Form SC 13G/A filed by Histogen Inc. (Amendment)

    2/11/22 7:06:22 AM ET
    $HSTO
    Biotechnology: Pharmaceutical Preparations
    Health Care
    Get the next $HSTO alert in real time by email
    SC 13G/A 1 ea155266-13ga1intra_histogen.htm AMENDMENT NO. 1 TO SCHEDULE 13G

     

     

    UNITED STATES
    SECURITIES AND EXCHANGE COMMISSION
    Washington, D.C. 20549

     

    SCHEDULE 13G

     

    Under the Securities Exchange Act of 1934

     

    (Amendment No. 1)*

     

    Histogen Inc.

     

    (Name of Issuer)

     

    Common Stock, $0.0001 par value per share

     

    (Title of Class of Securities)

     

    43358Y103

     

    (CUSIP Number)

     

    December 31, 2021

     

    (Date of Event Which Requires Filing of this Statement)

     

    Check the appropriate box to designate the rule pursuant to which this Schedule is filed:

     

    a.☐ Rule 13d-1(b)
    b.☒ Rule 13d-1(c)
    c.☐ Rule 13d-1(d)

     

    *The remainder of this cover page shall be filled out for a reporting person’s initial filing on this form with respect to the subject class of securities, and for any subsequent amendment containing information which would alter the disclosures provided in a prior cover page.

     

    The information required in the remainder of this cover page shall not be deemed to be “filed” for the purpose of Section 18 of the Securities Exchange Act of 1934 (“Act”) or otherwise subject to the liabilities of that section of the Act but shall be subject to all other provisions of the Act (however, see the Notes).

     

     

     

    Page 1 of 6

     

     

    CUSIP No. 43358Y103  

     

    1. Names of Reporting Persons.
       
      Mitchell P. Kopin
    2. Check the Appropriate Box if a Member of a Group (See Instructions)
       
      (a) ☐
      (b) ☐
    3. SEC Use Only
         
    4. Citizenship or Place of Organization United States of America
         

    Number of

    Shares Beneficially

    Owned by Each

    Reporting

    Person With:

    5. Sole Voting Power 0
         
    6. Shared Voting Power 5,282,710
         
    7. Sole Dispositive Power 0
         
    8. Shared Dispositive Power 5,282,710
           
    9. Aggregate Amount Beneficially Owned by Each Reporting Person 5,282,710 (see Item 4)
         
    10. Check if the Aggregate Amount in Row (9) Excludes Certain Shares (See Instructions) ☐
         
    11. Percent of Class Represented by Amount in Row (9) 9.99% (see Item 4)
         
    12. Type of Reporting Person (See Instructions)  
         
      IN; HC  

     

    Page 2 of 6

     

     

    CUSIP No. 43358Y103  

     

    1. Names of Reporting Persons.
       
      Daniel B. Asher
    2. Check the Appropriate Box if a Member of a Group (See Instructions)
       
      (a) ☐
      (b) ☐
    3. SEC Use Only
         
    4. Citizenship or Place of Organization United States of America
         

    Number of

    Shares Beneficially

    Owned by Each

    Reporting

    Person With:

    5. Sole Voting Power 0
         
    6. Shared Voting Power 5,282,710
         
    7. Sole Dispositive Power 0
         
    8. Shared Dispositive Power 5,282,710
           
    9. Aggregate Amount Beneficially Owned by Each Reporting Person 5,282,710 (see Item 4)
         
    10. Check if the Aggregate Amount in Row (9) Excludes Certain Shares (See Instructions) ☐
         
    11. Percent of Class Represented by Amount in Row (9) 9.99% (see Item 4)
         
    12. Type of Reporting Person (See Instructions)  
         
      IN; HC  

     

    Page 3 of 6

     

     

    CUSIP No. 43358Y103

     

    1. Names of Reporting Persons.
       
      Intracoastal Capital LLC
    2. Check the Appropriate Box if a Member of a Group (See Instructions)
       
      (a) ☐
      (b) ☐
    3. SEC Use Only
         
    4. Citizenship or Place of Organization Delaware
         

    Number of

    Shares Beneficially

    Owned by Each

    Reporting

    Person With:

    5. Sole Voting Power 0
         
    6. Shared Voting Power 5,282,710
         
    7. Sole Dispositive Power 0
         
    8. Shared Dispositive Power 5,282,710
           
    9. Aggregate Amount Beneficially Owned by Each Reporting Person 5,282,710 (see Item 4)
         
    10. Check if the Aggregate Amount in Row (9) Excludes Certain Shares (See Instructions) ☐
         
    11. Percent of Class Represented by Amount in Row (9) 9.99% (see Item 4)
         
    12. Type of Reporting Person (See Instructions)  
         
      OO  

     

    Page 4 of 6

     

     

    This Amendment No. 1 is being filed jointly by the Reporting Persons and amends the Schedule 13G initially filed by the Reporting Persons with the Securities and Exchange Commission (the “SEC”) on January 8, 2021 (the “Schedule 13G”).

     

    Except as set forth below, all Items of the Schedule 13G remain unchanged. All capitalized terms not otherwise defined herein shall have the meanings ascribed to such terms in the Schedule 13G.

     

    Item 4. Ownership.

     

    (a) and (b):

     

    As of the close of business on December 31, 2021, each of the Reporting Persons may have been deemed to have beneficial ownership of 5,282,710 shares of Common Stock, which consisted of (i) 2,352,942 shares of Common Stock held by Intracoastal, (ii) 2,352,942 shares of Common Stock issuable upon exercise of a warrant held by Intracoastal (“Intracoastal Warrant 1”) and (iii) 576,826 shares of Common Stock issuable upon exercise of a second warrant held by Intracoastal (“Intracoastal Warrant 2”), and all such shares of Common Stock represented beneficial ownership of approximately 9.99% of the Common Stock, based on (1) 49,950,212 shares of Common Stock outstanding as of December 21, 2021 as reported by the Issuer, plus (2) 2,352,942 shares of Common Stock issuable upon exercise of Intracoastal Warrant 1 and (3) 576,826 shares of Common Stock issuable upon exercise of Intracoastal Warrant 2. The foregoing excludes (I) 423,174 shares of Common Stock issuable upon exercise of Intracoastal Warrant 2 because Intracoastal Warrant 2 contains a blocker provision under which the holder thereof does not have the right to exercise Intracoastal Warrant 2 to the extent (but only to the extent) that such exercise would result in beneficial ownership by the holder thereof, together with the holder’s affiliates, and any other persons acting as a group together with the holder or any of the holder’s affiliates, of more than 9.99% of the Common Stock and (II) 1,454,552 shares of Common Stock issuable upon exercise of a third warrant held by Intracoastal (“Intracoastal Warrant 2”) because Intracoastal Warrant 3 contains a blocker provision under which the holder thereof does not have the right to exercise Intracoastal Warrant 3 to the extent (but only to the extent) that such exercise would result in beneficial ownership by the holder thereof, together with the holder’s affiliates, and any other persons acting as a group together with the holder or any of the holder’s affiliates, of more than 9.99% of the Common Stock. Without such blocker provisions, each of the Reporting Persons may have been deemed to have beneficial ownership of 7,160,436 shares of Common Stock.

     

    (c) Number of shares as to which each Reporting Person has:

     

    (i) Sole power to vote or to direct the vote: 0.

     

    (ii) Shared power to vote or to direct the vote: 5,282,710.

     

    (iii) Sole power to dispose or to direct the disposition of 0.

     

    (iv) Shared power to dispose or to direct the disposition of 5,282,710.

     

    Item 10. Certification

     

    By signing below I certify that, to the best of my knowledge and belief, the securities referred to above were not acquired and are not held for the purpose of or with the effect of changing or influencing the control of the issuer of the securities and were not acquired and are not held in connection with or as a participant in any transaction having that purpose or effect, other than activities solely in connection with a nomination under §240.14a-11.

     

    Page 5 of 6

     

     

    SIGNATURE

     

    After reasonable inquiry and to the best of my knowledge and belief, I certify that the information set forth in this statement is true, complete and correct.

     

    Date: February 11, 2022

     

      /s/ Mitchell P. Kopin
      Mitchell P. Kopin
       
      /s/ Daniel B. Asher
      Daniel B. Asher

     

      Intracoastal Capital LLC
         
      By: /s/ Mitchell P. Kopin
        Mitchell P. Kopin, Manager

     

    Page 6 of 6

     

    Get the next $HSTO alert in real time by email

    Chat with this insight

    Save time and jump to the most important pieces.

    Recent Analyst Ratings for
    $HSTO

    DatePrice TargetRatingAnalyst
    8/30/2021$2.40Buy
    HC Wainwright & Co.
    More analyst ratings

    $HSTO
    Press Releases

    Fastest customizable press release news feed in the world

    See more
    • Histogen Announces Second Adjournment of Special Meeting of Stockholders

      Meeting Adjourned for a Final Time to January 4, 2024 at 8:00 a.m. PTPotential Estimated Cash Distribution to Shareholders of $0.30 to $0.41 if Dissolution Proposal Approved SAN DIEGO, Dec. 14, 2023 (GLOBE NEWSWIRE) -- Histogen Inc. (OTC:HSTO), today announced that its special meeting of stockholders (the "Special Meeting") has been adjourned to Thursday, January 4, 2024 at 8:00 a.m. Pacific Time with respect to both proposals described in its definitive proxy statement filed with the U.S. Securities and Exchange Commission (the "SEC") on October 18, 2023 (the "Proxy Statement"). The Special Meeting, which will be reconvened for a final time on January 4, 2024, will continue to be held v

      12/14/23 4:15:00 PM ET
      $HSTO
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Histogen Announces Adjournment of Special Meeting of Stockholders

      SAN DIEGO, Dec. 05, 2023 (GLOBE NEWSWIRE) -- Histogen Inc. (OTC:HSTO) today announced that its special meeting of stockholders (the "Special Meeting") has been adjourned to Thursday, December 14, 2023 at 8:00 a.m. Pacific Time with respect to both proposals described in its definitive proxy statement filed with the U.S. Securities and Exchange Commission (the "SEC") on October 18, 2023 (the "Proxy Statement"). The reconvened Special Meeting on December 14, 2023 will continue to be held via live webcast at www.virtualshareholdermeeting.com/HSTO2023SM. In addition, the record date for determining stockholders entitled to vote at the Special Meeting will remain the close of business on Octob

      12/5/23 4:05:00 PM ET
      $HSTO
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Histogen Announces Board Approval of Complete Liquidation and Dissolution

      SAN DIEGO, Sept. 18, 2023 (GLOBE NEWSWIRE) -- Histogen Inc. (NASDAQ:HSTO), today announced that its Board of Directors, after extensive consideration of potential strategic alternatives, has approved and adopted a Plan of Dissolution ("Plan of Dissolution") that would include the distribution of remaining cash to stockholders following an orderly wind down of the company's operations, including any proceeds from the potential sale of any pipeline assets. In order to reduce costs and in connection with the Plan of Dissolution, the company has discontinued all clinical development programs and reduced its workforce, including the anticipated termination of most employees by the end of Septem

      9/18/23 4:05:04 PM ET
      $HSTO
      Biotechnology: Pharmaceutical Preparations
      Health Care